-
Management cites early success in real-world clinical practice consistent with trial data, with patients experiencing nearsightedness benefits within 30 minutes of a full day of practice.
-
The launch strategy prioritizes a ‘first sample’ approach to drive natural selection, which executives believe creates a long-term, sticky patient base despite NRx’s slow initial ramp compared to historical phase-in launches.
-
Performance data shows higher productivity among top registrars, with the top 1,000 physicians completing more than 40% more prescriptions per physician than VUITY’s comparable startup.
-
Management identified a ‘conceptual barrier’ where many ECPs initially viewed the product only in early presbyops; the strategic message revolves around highlighting the effectiveness of moderate to advanced events, LASIK patients, and contact lens wearers.
-
The company uses a position of financial strength, ending in 2025 with more than $292 million to finance the expansion of 33% of the sales force to 117 representatives.
-
The strategic position focuses on the product as the only once-a-day drop for 128 million Americans, aiming to establish a new level of care in an underserved market.
-
Management expects a meaningful impact on text volume in the second quarter of 2026 as the direct-to-consumer (DTC) campaign completes its typical two-quarter maturity cycle.
-
The expansion of the sales force to 117 reps is expected to be fully installed in Q2 2026, aiming to increase the frequency of calls and reach approximately 15,000 ECPs.
-
Financial guidance assumes a stable gross-to-net ratio of approximately 90 percent, resulting in a fixed net profit per unit of $60 per monthly package.
-
The international strategy targets more than 10 global regulatory submissions by the end of 2026, with possible approvals in many jurisdictions expected in early 2027.
-
A trial of direct TV advertising in selected high performing markets will be launched in April 2026 to assess consumer response and expand the media mix beyond digital channels.
-
Q4 2025 product revenue reached $1.6 million in the first half of the launch, with more than 20,000 paid and filled orders.
-
SG&A expenses increased 43% sequentially to $39.6 million, primarily driven by sales force establishment and non-recurring investments for the Q1 2026 DTC launch.
-
R&D expenses dropped to zero in Q4 after the completion of Phase III trials and subsequent product approval, shifting the company’s focus entirely to commercialization.
-
Management has confirmed a free balance sheet with a quarterly cash burn rate expected to remain low through 2026.
Our analysts recently identified a stock that has the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 choice. Tap here.
-
Management estimates more than 90% of new patients receive a sample before their first prescription, which filters out those who find the product effective.
-
Early data shows patients switching from 1 to 3 months given by management as a sign of high commitment and product satisfaction.
-
Administrators strongly dispute the ‘heritage’ assumption that eye drop only works for early presbyopes by showing ECPs data that middle to advanced patients tend to get more visual lines.
-
The sales team trains ECPs in ’10 seconds’ to integrate the product into routine exams for all eligible patients, including those with prior LASIK.
-
Website traffic is currently 5x higher than baseline, with spikes of up to 10x during the national activation, although management noted that it takes time to convert awareness into appointments.
-
Although the direct correlation from web click to script has not been fully established, raising brand awareness early on YouTube works 2x more than industry averages.
-
Management characterized their 117-rep stretch as a ‘moderately sized’ strength compared to the nearly 300 reps used during VUITY’s launch.
-
The team is seeing a significant number of ‘NA’ doctors—those who have never prescribed VUITY—now using VIZZ, suggesting the product is expanding the overall market rather than just trading share.
One stock. Nvidia-grade power. 30M+ investors hope Moby gets it first. Get a choice. Tap here.
